Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:alternativeName |
gptkb:efinaconazole
|
| gptkbp:approvalYear |
2014
|
| gptkbp:approvedBy |
gptkb:Japan
gptkb:United_States |
| gptkbp:ATCCode |
D01AC18
|
| gptkbp:CASNumber |
164650-44-6
|
| gptkbp:chemicalFormula |
C18H22F2N4O
|
| gptkbp:developedBy |
gptkb:Merck_&_Co.
|
| gptkbp:drugClass |
triazole antifungal
|
| https://www.w3.org/2000/01/rdf-schema#label |
MK-0518
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Jublia
|
| gptkbp:mechanismOfAction |
inhibits fungal lanosterol 14α-demethylase
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
topical
|
| gptkbp:sideEffect |
application site dermatitis
blistering ingrown toenail |
| gptkbp:usedFor |
treatment of onychomycosis
|
| gptkbp:bfsParent |
gptkb:raltegravir
|
| gptkbp:bfsLayer |
6
|